PHILADELPHIA, PA; June 5, 2024 – Quotient Sciences, the drug development and manufacturing accelerator, has announced changes to its operational leadership team for its Philadelphia, Pa. facilities. Marlene Leuenberger has joined as Vice President and General Manager of Quotient Sciences’ Philadelphia facilities.
In this Pharmafile Magazine article Nazim Kanji and Huw Jones explore the orphan drug development and the benefit of CRO/CDMO collaboration, specifically in terms of pediatric rare diseases.
Highlights from CPHI North America 2024: Round-up by Life Sciences Knowledge Hub
Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical stage pharmaceutical company developing innovative solutions for pain relief that reduce the potential for opioid abuse and overdose, recently announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.
Pharmaceutical Outsourcing Roundtable: Pediatric Dosage Forms with Nazim Kanji
Quotient`s Lewis Wins 2024 CRS Distinguished Service Award
In a recent interview with Outsourcing Pharma, Dr. Vanessa Zann, Senior Drug Development Consultant, speaks about her experience and the impact that Quotient Sciences has on drug development.
DCAT Interview Life Sciences Hub`s Thierry Van Nieuwenhove
NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.
Quotient Sciences Wins 2024 CRO Leadership Awards